A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-559 in the Treatment of Patients With Type 2 Diabetes Mellitus.

Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-559 in the Treatment of Patients With Type 2 Diabetes Mellitus.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Imiglitazar; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 18 Dec 2008 Planned patient number added (348) as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Actual end date (Dec 2004) added as reported by ClinicalTrials.gov.
    • 16 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top